Asia-Pacific Acute Care Syndromic Testing Market Outlook Report 2023-2033 – Overall Reduced Cost of Care Due to Early Diagnosis with Syndromic Testing

DUBLIN, Feb. 12, 2024 /PRNewswire/ — The “Asia-Pacific Acute Care Syndromic Testing Market: Analysis and Forecast, 2023-2033” report has been added to’s offering.

The Asia-Pacific acute care syndromic testing market was valued at $0.78 billion in 2023 and is expected to reach $2.20 billion by 2033, growing at a CAGR of 10.97% between 2023 and 2033. The growth of the market can be attributed to the rising need for early detection of infectious diseases, driven by the growing incidence of such diseases, the occurrence of pandemics, and the identification of new infectious diseases in various regions, exacerbated by global warming.

The Asia-Pacific (APAC) acute care syndromic testing market is experiencing robust growth and increasing prominence in the region’s healthcare landscape. Syndromic testing plays a pivotal role in rapidly diagnosing and managing acute illnesses, offering a timely response to outbreaks and emergencies. This market’s expansion is driven by factors such as the rising incidence of infectious diseases, growing awareness of the importance of early diagnosis, and advancements in diagnostic technologies.

In recent years, APAC has witnessed significant investments in healthcare infrastructure and the adoption of innovative diagnostic solutions. These investments have bolstered the acute care syndromic testing market, enabling quicker and more accurate diagnoses in emergency and critical care settings. Furthermore, the ongoing COVID-19 pandemic has underscored the critical role of syndromic testing in public health response, further fueling the demand for such testing solutions across the APAC region.

Market Segmentation:

Segmentation by End User

  • Hospitals
  • Clinical and Diagnostic Laboratories
  • Research and Academic Institutions
  • Other End Users

Segmentation by Country

  • Japan
  • India
  • China
  • South Korea
  • Australia
  • Rest-of-Asia-Pacific

Competitive Strategy:

The APAC acute care syndromic testing market has numerous startups paving their way into manufacturing kits, panels, assays, and instruments and entering the market. Key players in the APAC acute care syndromic testing market analyzed and profiled in the study involve established players that offer various kinds of disease-specific panels and multiplex instruments.

Key Market Players and Competition Synopsis

Some prominent names established in this market are:

Key Topics Covered:

Executive Summary

1 Markets
1.1 Market Scope
1.1.1 Key Questions Answered in the Report
1.2 Research Methodology

2 Market Overview
2.1 Overview
2.2 Acute Care Syndromic Testing Workflow Analysis
2.3 Market Footprint and Growth Potential
2.4 Future Potential

3 Industry Insight
3.1 Stakeholder’s Perspective (N=20)
3.1.1 Physician’s Perception
3.1.2 Payor’s Perception
3.1.3 Investor’s Perception
3.2 Legal and Regulatory Framework of the Acute Care Syndromic Testing Market
3.3 Product Benchmarking

4 Market Dynamics
4.1 Overview
4.2 Impact Analysis
4.3 Market Drivers
4.3.1 Faster Results Acquired with Syndromic Tests
4.3.2 Increasing Incidence of Infectious Diseases
4.3.3 Overall Reduced Cost of Care Due to Early Diagnosis with Syndromic Testing
4.3.4 Reduced Severe Adverse Effects from Pathogens
4.4 Market Challenges
4.4.1 Need for Better Policies with Respect to Acute Care Syndromic Test Reimbursement
4.4.2 Lack of High-Complexity Testing Centres
4.5 Market Opportunities
4.5.1 Quick Access to Treatment and Reduced Use of Antibiotics
4.5.2 High Number of Synergistic Activities and Mergers and Acquisitions (M&A) Over the Past Years

5 Acute Care Syndromic Testing Market (By Region), 2022-2033
5.1 Overview
5.2 Asia-Pacific
5.2.1 Asia-Pacific Acute Care Syndromic Testing Market, By End User
5.2.2 Asia-Pacific Acute Care Syndromic Testing Market, By Country

6 Company Profiles
6.1 Overview
6.2 Acute Care Syndromic Testing Ecosystem Active Players
6.3 Seegene Inc.
6.3.1 Company Overview
6.3.2 Role of Seegene, Inc. in the Acute Care Syndromic Testing Market
6.3.3 Financials
6.3.4 Recent Developments Corporate Strategies Business Strategies
6.3.5 Analyst Perspective
6.4 SpeeDx
6.4.1 Company Overview
6.4.2 Role of SpeeDX in the Acute Care Syndromic Testing Market
6.4.3 Analyst Perspective

For more information about this report visit

About is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo –

SOURCE Research and Markets

Originally published at—overall-reduced-cost-of-care-due-to-early-diagnosis-with-syndromic-testing-302059846.html
Images courtesy of